首页> 外文期刊>Free radical research >Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
【24h】

Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.

机译:去铁酮在β地中海贫血中的药理作用/与铁动力学相关的促氧化剂活性。

获取原文
获取原文并翻译 | 示例
       

摘要

The potential of free radical formation in serum of beta-thalassemia/Hb E patients receiving a single oral dose of 25 mg/kg body weight of deferiprone, a bidentate orally active iron chelator, was evaluated using EPR/spin trapping technique. In the presence of ascorbic acid and tert-butylhydroperoxide, EPR signals of ascorbyl radical (aH=0.18 mT) and DMPO-carbon centred adduct (aH=2.37 mT, aN=1.65 mT) were detected. Shortly after deferiprone administration, EPR signal intensities decreased concomitant with an increase in serum levels of deferiprone. Unfortunately, enhanced EPR signal intensities were observed at 300 min after dosing in patients with serum molar ratio of deferiprone to iron less than 3, suggesting the formation of incomplete iron-deferiprone complexes and consequently free radical formation. To avoid adverse effects of deferiprone, a dosage regimen should be designed according to iron status of the patients and aimed at maintaining an adequate ratio of serum chelator-to-iron concentration.
机译:使用EPR /旋转诱捕技术评估了接受25 mg / kg体重的单剂量口服口服铁螯合剂去铁酮的单次口服剂量的地中海贫血/ Hb E患者的血清中自由基形成的潜力。在抗坏血酸和氢过氧化叔丁基存在下,检测到抗坏血酸基团的EPR信号(aH = 0.18 mT)和DMPO-碳中心加合物(aH = 2.37 mT,aN = 1.65 mT)。给予去铁酮后不久,EPR信号强度下降,同时血清去铁酮水平升高。不幸的是,在去铁酮与铁的血清摩尔比小于3的患者中,给药后300分钟观察到增强的EPR信号强度,表明形成了不完全的铁-去铁酮复合物,并因此形成了自由基。为了避免去铁酮的不利影响,应根据患者的铁状况设计剂量方案,并旨在维持适当的血清螯合剂与铁浓度之比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号